AK 3012
A proprietary topical formulation. Upon subcutaneous administration, the active ingredient in AK 3012 may inhibit actinic keratosis.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.